Efficient Gene Transfer via Retrograde Transport in Rodent and Primate Brains Using a Human Immunodeficiency Virus Type 1-Based Vector Pseudotyped with Rabies Virus Glycoprotein
- 1 November 2007
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 18 (11) , 1141-1152
- https://doi.org/10.1089/hum.2007.082
Abstract
The primate lentiviral vector system based on human immunodeficiency virus type 1 (HIV-1) has been used for a wide range of gene therapy trials in animal models. Axonal transport in the retrograde direction, which is observed with some viral vectors, confers a considerable advantage to gene transfer into neuronal cell bodies that are localized in regions remote from the injection site of the vectors. However, retrograde axonal transport of the HIV-1-based lentiviral vector pseudotyped with vesicular stomatitis virus glycoprotein is reported to be inefficient. In the present study, we developed an efficient gene transfer system through retrograde transport in the brain with the HIV-1-based vector pseudotyped with rabies virus glycoprotein (RV-G). Injection of the RV-G-pseudotyped HIV-1 vector into the dorsal striatum of mice yielded an increase in gene transfer into neuronal populations in the cerebral cortex, thalamus, and ventral midbrain, each of which innervates the striatum. In addition, injection of the RV-G-pseudotyped vector into the monkey striatum (putamen) resulted in highly efficient transfer into neurons in the ventral midbrain (nigrostriatal dopamine neurons). Our results indicate that pseudotyping of the HIV-1 vector with RV-G enhances the efficiency of gene transfer through retrograde axonal transport in both mouse and monkey brains. This primate lentiviral vector system will provide a powerful approach to gene therapy for neurological and neurodegenerative diseases by means of enhanced retrograde transport.Keywords
This publication has 41 references indexed in Scilit:
- Simian immunodeficiency virus vector pseudotypes differ in transduction efficiency and target cell specificity in brainGene Therapy, 2007
- Parkin Protects against Neurotoxicity in the 6-Hydroxydopamine Rat Model for Parkinson's DiseaseMolecular Therapy, 2006
- 1‐methyl‐4‐phenylpyridinium neurotoxicity is attenuated by adenoviral gene transfer of human Cu/Zn superoxide dismutaseJournal of Neuroscience Research, 2005
- Lentivirus-mediated expression of glutathione peroxidase: Neuroprotection in murine models of Parkinson's diseaseNeurobiology of Disease, 2005
- Administration of a Replication-Deficient Adeno-Associated Virus Gene Transfer Vector Expressing the HumanCLN2cDNA to the Brain of Children with Late Infantile Neuronal Ceroid LipofuscinosisHuman Gene Therapy, 2004
- Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's diseaseGene Therapy, 2002
- Production and Neurotropism of Lentivirus Vectors Pseudotyped with Lyssavirus Envelope GlycoproteinsMolecular Therapy, 2001
- Neuroprotection of Spinal Motoneurons Following Targeted Transduction with an Adenoviral Vector Carrying the Gene for Glial Cell Line-Derived Neurotrophic FactorExperimental Neurology, 1998
- Efficient selection for high-expression transfectants with a novel eukaryotic vectorGene, 1991
- VSV binding to lipids from different cell linesArchiv für die gesamte Virusforschung, 1987